MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.785
AS - Asia 9.156
EU - Europa 8.758
SA - Sud America 1.158
OC - Oceania 549
Continente sconosciuto - Info sul continente non disponibili 426
AF - Africa 415
Totale 41.247
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.010
GB - Regno Unito 2.985
SG - Singapore 1.991
CN - Cina 1.725
IT - Italia 1.460
HK - Hong Kong 917
VN - Vietnam 869
DE - Germania 849
BR - Brasile 822
SE - Svezia 632
PH - Filippine 567
CA - Canada 529
AU - Australia 502
TR - Turchia 469
FI - Finlandia 446
FR - Francia 441
BD - Bangladesh 369
RU - Federazione Russa 340
IN - India 298
UA - Ucraina 289
IR - Iran 288
KR - Corea 208
PK - Pakistan 193
ID - Indonesia 165
JP - Giappone 157
NL - Olanda 145
IE - Irlanda 140
MY - Malesia 125
ES - Italia 122
BG - Bulgaria 119
PL - Polonia 117
ZA - Sudafrica 113
AR - Argentina 109
MX - Messico 104
GR - Grecia 100
SA - Arabia Saudita 95
IQ - Iraq 87
IL - Israele 85
TW - Taiwan 85
MA - Marocco 77
BE - Belgio 71
AT - Austria 66
NP - Nepal 60
TH - Thailandia 60
AE - Emirati Arabi Uniti 57
EC - Ecuador 52
RO - Romania 49
LK - Sri Lanka 47
CO - Colombia 46
NZ - Nuova Zelanda 46
JO - Giordania 44
KE - Kenya 44
NO - Norvegia 44
GE - Georgia 39
EG - Egitto 38
LT - Lituania 36
CH - Svizzera 35
CL - Cile 34
LV - Lettonia 34
PT - Portogallo 31
CZ - Repubblica Ceca 30
EE - Estonia 30
HR - Croazia 25
NG - Nigeria 23
VE - Venezuela 23
HU - Ungheria 22
TN - Tunisia 22
BA - Bosnia-Erzegovina 21
UZ - Uzbekistan 21
JM - Giamaica 20
PE - Perù 20
SI - Slovenia 18
SK - Slovacchia (Repubblica Slovacca) 18
DZ - Algeria 17
OM - Oman 17
PY - Paraguay 17
BZ - Belize 15
CR - Costa Rica 15
BH - Bahrain 14
BO - Bolivia 14
UG - Uganda 14
PR - Porto Rico 13
TT - Trinidad e Tobago 13
UY - Uruguay 13
LB - Libano 12
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
CY - Cipro 10
DK - Danimarca 10
ET - Etiopia 10
NI - Nicaragua 10
MU - Mauritius 9
PA - Panama 9
PS - Palestinian Territory 9
KZ - Kazakistan 8
QA - Qatar 8
SV - El Salvador 8
LY - Libia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
Totale 40.676
Salva come PNG Salva come JPEG
Città #
Ashburn 2.166
Fairfield 1.815
Southend 1.619
Santa Clara 1.441
Singapore 1.244
Woodbridge 1.143
Chandler 839
Houston 837
Hong Kong 818
San Jose 790
Seattle 695
Wilmington 659
Cambridge 591
Jacksonville 509
Council Bluffs 434
Dearborn 428
Ann Arbor 404
Nyköping 401
Beijing 382
Hefei 370
Los Angeles 354
London 342
Helsinki 332
New York 291
Chicago 279
Ho Chi Minh City 276
Modena 231
Hanoi 230
Frankfurt am Main 224
Redwood City 183
Milan 182
Munich 180
San Diego 180
The Dalles 167
Izmir 154
Dallas 134
Seoul 130
Shanghai 123
Princeton 116
Sofia 113
Salt Lake City 111
Buffalo 107
Melbourne 106
São Paulo 98
Columbus 96
Eugene 96
Moscow 94
Lauterbourg 88
Jakarta 81
Tokyo 79
Sydney 78
Manchester 77
Dublin 76
Istanbul 71
Phoenix 71
Ottawa 62
Brisbane 61
Toronto 60
Bremen 59
Boardman 58
Bologna 57
Rome 54
Elk Grove Village 53
Warsaw 53
Montreal 50
Tampa 49
Atlanta 48
Paris 48
Falls Church 47
Taipei 46
Athens 43
Boston 43
Liverpool 43
Quezon City 43
Johannesburg 42
Da Nang 41
Denver 41
Des Moines 41
Miami 41
Brussels 40
Casablanca 38
Orem 38
Tehran 38
Colombo 37
Fremont 37
Kuala Lumpur 37
Philadelphia 37
Karachi 36
North Bergen 36
Islamabad 35
Lahore 35
Riyadh 35
Brooklyn 34
Dong Ket 34
Stockholm 34
Amsterdam 32
Birmingham 32
Cebu City 32
Manila 32
Perth 32
Totale 25.059
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 7.092
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 724
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 644
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 636
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 564
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 557
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 544
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 512
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 488
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 484
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 471
Empathic attitudes among nursing students: a preliminary study 434
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 432
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 420
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 403
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 400
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 400
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 394
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 393
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 391
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 391
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 385
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 378
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 373
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 373
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 372
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 363
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 362
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 361
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 356
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 354
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 352
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 348
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 345
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 338
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 336
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 332
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 332
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 330
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 330
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 330
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 330
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 329
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 328
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 323
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 322
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 320
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 320
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 320
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 319
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 319
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 318
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 318
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 318
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 317
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 317
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 313
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 310
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 307
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 305
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 304
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 301
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 297
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 296
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 295
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 293
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 292
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 289
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 289
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 283
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 281
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 280
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 280
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 275
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 271
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 269
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 267
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 261
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 260
Twenty-years experience with de novo metastatic breast cancer 252
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 251
I tumori nelle provincie di Parma, Reggio Emilia, Modena 249
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 248
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 248
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 246
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 242
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 239
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 237
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 235
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment 229
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 225
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 225
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 223
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 221
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 220
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 218
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 212
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 212
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 207
Totale 40.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.314 0 0 0 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/202610.466 658 424 690 1.193 1.679 785 1.181 522 959 975 806 594
2026/20272.359 368 801 721 469 0 0 0 0 0 0 0 0
Totale 41.247